"Tipranavir (Aptivus) before darunavir (Prezista) increases susceptibility to darunavir for the circulating virus population. The impact of archived mutations on durable response to subsequent treatment with darunavir is unknown and can only be determined by clinical investigation."
Regards,
Nelson Vergel
powerusa dot org
See what's free at AOL.com.